High blood pressure and calcium antagonism

Cardiology (Switzerland)

Volumn 88, Issue , 1997, Pages 39-46

  Palma Gámiz, José L ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Calcium channel blockers; Calcium regulation; Hypertension

Indexed keywords

AMLODIPINE; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM ION; DILTIAZEM; FELODIPINE; GALLOPAMIL; ISRADIPINE; LACIDIPINE; NICARDIPINE; NIFEDIPINE; NIMODIPINE; NISOLDIPINE; NITRENDIPINE; VERAPAMIL;

ANKLE EDEMA; BLOOD PRESSURE REGULATION; BRADYCARDIA; CALCIUM ANTAGONISM; CALCIUM HOMEOSTASIS; CALCIUM TRANSPORT; CARDIOVASCULAR EFFECT; CARDIOVASCULAR FUNCTION; CONFERENCE PAPER; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM; DRUG METABOLISM; DRUG RECEPTOR BINDING; FLUSHING; HEADACHE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HEART VENTRICLE FUNCTION; HUMAN; HYPERTENSION; NOSE CONGESTION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM; SIDE EFFECT; SMOOTH MUSCLE TONE; TACHYCARDIA; VASCULAR RESISTANCE; VASODILATATION;

CALCIUM; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR SYSTEM; HUMANS; HYPERTENSION; SARCOPLASMIC RETICULUM; VASCULAR RESISTANCE; VASOCONSTRICTION;

EID: 0031021243     PISSN: 00086312     EISSN: 14219751     Source Type: Journal    
DOI: 10.1159/000177461     Document Type: Article

References (56)

1. Fleckestein A: Historical overview: The calcium channels of the heart. Ann NY Acad Sci 1988:522:1-15.
2. Spedding M. Paoletti R: Classification of calcium channels and the sites of action of drugs modifying channel function. Pharmacol Rev 1992:44:363-401.
3. Naylcr WG: Calcium Antagonists. London. Academic Press, 1988.
4. Heidland A, Klütsch K. Oebeck A: Myogenbe-dingtc Vasodilatation bei Nicrcnischamie. Münch Med Wochenschr 1962:35:1636- 1637.
5. Frishman WH, Rosenberg A. Katz B: Calcium, antagonists in the management of systemic hypertension: The impact of sustained-release drug-delivery systems. Coron Artery Dis 1994: 5:4-13.
6. + channels. J Biol Chcm 1992:267:1403-1406.
7. 2+ channels. Trends Pharmacol Sci 1991; 12:344-353.
8. Naylcr WG: Second Generation of Calcium Antagonists. Berlin. Springer. 1991
9. Kaplan NM: Calcium entry blockers in the treatment of hypertension. Current status and future prospects. JAMA 1989:262:817-823.
10. Weiner DA: Calcium channel blockers. Med Clin North Am 1988;72:83-115.
11. Katz AM. Leach NM: Differential effects of the 1.4-dihvdropyridine calcium channel blockers: Therapeutic implications. J Clin Pharmacol 1987;27:825-834.
12. Swales JD: Calcium antagonists: in Swales JD (ed): Textbook of Hypertension. Oxford. Black-well Scientific Publications, 1994, pp 1111- 1114.
13. Maxwell DJ. Crawford DC. Curry PV, Tynan MJ, Allan LD: Obstetric importance, diagnosis. and management of fetal tachycardias. BMJ 1988:297:107-110.
14. Kleinman CS: Prenatal diagnosis, and management of intrauterine arrhythmias. Fetal Ther 1986:1:92-95.
15. Truccone M. Mariona F: Intrauterine conversion of fetal supraventricular tachycardia with combination of digoxin and verapamil. Pediatr Pharmacol 1985:5:149-153.
16. Klein V. Repke JT: Supraventricular tachycardia in pregnancy: Cardioversion with verapamil. Obstct Gynecol 1984:63(suppl 3): 16S- 18S.
17. Zanchctti A: Role of calcium antagonists in systemic hypertension. Am J Cardiol 1987:59: 130B-136B.
18. Kiowski W. Bertel O. Erne P. Hulthcn UL. Bolli P. Ritz R. Buhler FR: Haemodynamic and reflex mechanisms of acute and chronic antihypertensive therapy with a calcium channel blocker nifedipine. Hypertension 1983: 5(suppl I): 170-174.
19. Psaty BM. Hcckbert SR, Koepsell TD, Sisco-vick DS. Raghunathan TE, Weiss NS. Roscn-daal FA. Lemaitre RN. Smith NL. Wahl PW. Wagner EH. Furbcrg CD: The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995:274:620-625.
20. Sleight P: Are antianginal drugs effective in postmyocardial infarction secondary prevention. Eur Heart J 1995; 16(suppl H):36-37.
21. Glasser SP. Clark PL, Lipicky RJ. Hubbard JM. YusufS: Exposing patients with chronic stable, exertional angina to placebo periods in drug trials. JAMA 1991:265:1550-1554.
22. Dahldf B. Penncrt K. Hansson L: Reversal of left ventricular hypertrophy in hypertensive patients. A meta-analysis of 109 treatment studies. Am J Hypcrtens 1992:5:95-110.
23. Mulvany MJ: The development and regression of vascular hypertrophy. J Cardiovasc Pharmacol 1992:19(suppl 2):S22-S27.
24. Frombach R. Reil GH. Schiittc C. Jost S. Gul-ba D. Liehtlen PR: Effects of nisoldipinc on intact and endothelium-denuded vascular ring preparations: in Lichtlcn PR. KrayenbUhl HP (eds): New Aspects on Nisoldipine. Stuttgart. Schattauer, 1990. pp 51-60.
25. Paoletti R. Bernini A: A new generation of calcium antagonists and their role in atherosclerosis. Am J Cardiol 1990;66:28H-31H.
26. Triggle DJ: Calcium-channel drugs: Structure-function relationship and selectivity of action. J Cardiovasc Pharmacol 1991:18(suppl 10): S1-S6.
27. Pahor M, Guralnik JM. Corti CM, Foley DJ. Carbcnin P. Havlik RJ: Long-term survival and use of antihypertensive medications in older persons. J Am Geriatr Soc 1995:43:1191-1197.
28. Pahor M, Guralnik JM. Furberg CD. Carbonin P. Havlik R: Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old. Lancet 1996:347: 1061-1065.
29. Pahor M. Guralnik JM. Salivc ME, Coni MC. Carbonin P. Havlik RJ: Do calcium channel blockers increase the risk of cancer? Am J Hypertcns 1996:9:695-699.
30. Alderman MH: More news about calcium antagonists. Am J Hypertens 1996;9:710-712.
31. Morris AD. Reid JL: Cardiovascular selectivity and clinical applications of calcium antagonists. J Cardiovasc Pharmacol 1992: 20(suppl A):S25-S32.
32. Danish Study Group on Verapamil in Myocardial Infarction: Verapamil in acute myocardial infarction. BrJ Clin Pharmacol 1986:21:197S- 204S.
33. Multiccntcr Diltiazem Postinfarction Trial Research Group: The effect of diltiazem on mortality and reinfarction after myocardial infarction! N Engl J Med 1988:319:385-392.
34. HINT Research Group (Holland Intcruniversi-ty Nifedipine/Metoprolol Trial): Early treatment of unstable angina in the coronary care unit. A randomized double-blind placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986:56:400-413.
35. Fleckestcin A, Frey M, Zorn J. Fleckestein-Grun G: Amlodipine, a new 1.4-dihydropyrid-inc calcium antagonist with a particularly strong antihypertensive profile. Am J Cardiol 1989:64:211-341.
36. Soward AL, De Feyter PJ, Hugenholtz PG: Maintenance of increased coronary blood flow in excess of demand by nisoldipine administered as an intravenous infusion. Am J Cardiol 1986;58:1204-1208.
37. Tamargo J. Delpon E: Dihydropyridines and vascular diseases. Z Cardiol 199l:80(suppl 7): 106-111.
38. Kimichi A. Lewis BS: Calcium antagonists and the management of heart failure: in Lewis BS. Kimichi A (eds): Heart Failure: Mechanisms and Management. Berlin. Springer. 1991. pp 281-292.
39. Furberg CD. Psaty BM. Meyer JV: Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 1995: 92:1326-1331.
40. Wilcox RG. Hampton JR, Banks DC. Birkhcad JS. Brooksby IAB. Burns-Cox CJ. Hayes MJ. Joy MD. Malxolm AD. Mather HG. Rowley JM: Trial of early nifedipine in acute myocardial infarction: The Trent Study. BMJ 1986: 293:1204-1208.
41. Pahor M. Guralnik JM. Corli MC. Foley DJ. Carbonin P, Havlik RJ: Long-term survival and useofantihypertensivc medications in older persons. J Am Geriatr Soc 1995:43:1191-1197.
42. Goldbourt U, Behar S, Rcichcr-Rciss H. Zion M. Mandclzweig L. Kaplinsky E: Early administration of nifedipine in suspected acute myocardial infarction. The Secondary Prevention Rcinfarction Israel Nifedipine Trial 2 Study (SPRINT Study Group). Arch Intern Med 1993:153:345-353.
43. Findlay AN. MacLeod K, Gillen G, Telliott A. Aitchison T, Dargie HJ: A double-blind placebo control comparison of verapamil, atenolol and their combination in patients with chronic stable angina pectoris. Br Heart J 1987:57: 336-343.
44. Gustafsson D: Microvascular mechanisms involved in calcium antagonists on myogenic and neurogenic control of resistance and capacitance vessels in cat skeletal muscle. J Cardiovasc Pharmacol 1988:12:413-422.
45. Gustafsson D. Grande PO. Borgstrom P. Lundberg L: Effects of calcium antagonists on myogenic and neurogenic control of resistance and capacitance vessels in cat skeletal muscle. J Cardiovasc Pharmacol 1988:12:413-422.
46. Mclandri G. Branzi A, Targagni F. Esposli D. Piazzi S, Motta R. Bargossi A. Fallani F. Mag-nan I: Myocardial metabolic and hemodynamic effects of sustained intravenous infusion of nifedipine with and without metoprolol in patients with unstable angina. Am Heart J 1991:121:44-51.
47. Burges RA: Review of the pharmacology of amlodipine. J Cardiovasc Pharmacol 1992: 20(suppl A):S1 -S5.
48. Leenen FHH. Holliwell DL; Antihypertensive effect of fclodipinc associated with persistent sympathetic activation and minimal regression of left ventricular hypertrophy. Am J Cardiol 1992:62:639-645.
49. Nelson MT. Yu Huang JF. Worley III: Membrane potential regulates inhibition of calcium channels in coronary arteries: in Lichtlcn PR. Krayenbuhl HP(eds): New Aspects on Nisoldipine. Stuttgart. Schattauer. 1990, pp 3-7.
50. Friedel HA. Sorkin EM: Nisoldipine. A preliminary review of its pharmacologic and pharmacokinetic properties and therapeutic efficacy in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 1988:36:682-731.
51. Lasseter KC, Muller O, Garrett BN, Marazzi P. Fodor JG: Pharmacokinetics, pharmacodynamics. and clinical utility of nisoldipine coal core in the treatment of essential hypertension. Cardiovasc Rev Rep 1996:17:28-46.
52. Abemcthy DR. Gutkowska J. Lambert MD: Amlodipine in the elderly hypertensive patients: Pharmacokinetics and pharmacodynamics. J Cardiovasc Pharmacol 1988. 12(suppl 7):S67-S71.
53. Frishman WH. Stroh JA, Greenberg S. Suarez T. Karp A. Peled H: Calcium channel blockers in systemic hypertension. Med Clin North Am 1988:72:449-499.
54. Saltiel E, Ellrodt AG. Monk JP. Langley MS: Fclodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension. Drugs 1988:36: 387-428.
55. Goa KL, Sorkin EM: Nitrendipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension. Drugs 1987:33: 123-155.
56. Sorkin EM. Clissold SP: Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs 1987; 33:296-345.